Myomo, Inc. (AMEX:MYO) Q4 2022 Earnings Call Transcript

Paul Lowry: Hey, good morning. Do you have an update on MyoPal?

Paul Gudonis: Yes. So we have restarted the development efforts on MyoPal. After COVID we had — we’ve progressed the development of the product. We had some patients come in for various testing and so on. And we’re now focusing our attention on enhancements to the MyoPro 2 plus. Now we’ve got several hundred of our flagship product out in the marketplace. We want to continue to keep improving that product. And then we plan to go back to MyoPal. And our plan right now is to have MyoPal out in the market in calendar year 2024.

Paul Lowry: And any update on the China venture?

Paul Gudonis: No. As I mentioned in my remarks and then Dave can jump in too. We’ve been in touch with Riser Medical, which is our partner there. COVID has certainly disrupted business operations trying to get into government offices to wire funds and so on. We had a visit from David Ren, the CEO of my Riser Medical back in August. He was able to visit our facilities here in Boston, went back and then, of course, you saw what happened in China everyone was locked down and everyone was allowed back out and that created a huge spike in cases. So that’s all I can tell you right now. Maybe Dave, you may have some other updates from the financial side.

Dave Henry: I think it’s just hard for us to know at this point. I mean, what they tell us is, it’s COVID and bureaucracy, but I have to believe what we’ve been hearing in news reports about the number of cases and things like that and all of the lockdowns and things, the business environment to start up a new business in China is probably not ideal. And so, I think that has had an impact as well. But we are pushing very hard and at some point here I think Riser, they need to fisher cut bait on the joint venture here, because we have — we would — there’s other opportunities that maybe we can pursue over there as well.

Paul Lowry: And any comment for the quarter on how much of the performance came from domestic versus international?